<p>Theravance Biopharma, Inc.（NASDAQ:TBPH - 获取免费报告）的股票在覆盖该股票的八家研究公司中获得了 “适度买入” 的平均评级，MarketBeat Ratings 报告称。四位分析师给予该股票持有评级，两位给予买入评级，两位给予强烈买入评级。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价为 21.8333 美元。</p>
<p>获取 <strong>Theravance Biopharma</strong> 的提醒：</p>
<p>TBPH 已成为几份分析师报告的主题。Zacks Research 在 3 月 19 日的研究报告中将 Theravance Biopharma 的股票评级从 “持有” 上调至 “强烈买入”。B. Riley Financial 在 4 月 7 日的研究报告中将 Theravance Biopharma 的股票目标价从 14.00 美元上调至 17.00 美元，并给予该股票 “中性” 评级。TD Cowen 在 3 月 23 日的研究报告中将 Theravance Biopharma 的股票目标价从 13.00 美元上调至 15.00 美元，并给予该股票 “持有” 评级。Weiss Ratings 在 4 月 10 日的研究报告中将 Theravance Biopharma 的股票评级从 “买入（b-）” 下调至 “持有（c+）”。最后，Oppenheimer 在 3 月 5 日的报告中将 Theravance Biopharma 的股票评级从 “跑赢大盘” 下调至 “市场表现”。</p>
<p><strong>查看我们关于 TBPH 的最新报告</strong></p>
<h2>Theravance Biopharma 股价上涨 0.9%</h2>
<p>NASDAQ TBPH 周五开盘价为 16.46 美元。该公司的 50 日移动平均价格为 16.14 美元，200 日移动平均价格为 17.20 美元。Theravance Biopharma 的一年低点为 8.33 美元，一年高点为 21.03 美元。该公司的市值为 8.4753 亿美元，市盈率为 8.11，贝塔值为 0.17。</p>
<h2>Theravance Biopharma 的内部活动</h2>
<p>在其他 Theravance Biopharma 的新闻中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。这些股票以平均价格 13.96 美元出售，总价值为 433,695.32 美元。交易后，这位高级副总裁直接持有 232,699 股公司股票，价值为 3,248,478.04 美元。此次交易使其持股减少了 11.78%。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。目前，6.90% 的股票由公司内部人士持有。</p>
<h2>对 Theravance Biopharma 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近修改了对 TBPH 的持股。AQR Capital Management LLC 在第一季度以约 101,000 美元的价格收购了 Theravance Biopharma 的新头寸。Jane Street Group LLC 在第一季度将其在 Theravance Biopharma 的股份增加了 169.2%。Jane Street Group LLC 现在拥有 140,884 股该生物制药公司的股票，价值为 1,258,000 美元，此前在上个季度又收购了 88,540 股。Creative Planning 在第二季度以约 139,000 美元的价格收购了 Theravance Biopharma 的新股份。American Century Companies Inc. 在第二季度将其在 Theravance Biopharma 的股份增加了 6.8%。American Century Companies Inc. 现在拥有 91,501 股该生物制药公司的股票，价值为 1,009,000 美元，此前在上个季度又购买了 5,794 股。最后，Invesco Ltd. 在第二季度将其在 Theravance Biopharma 的股份增加了 12.4%。Invesco Ltd. 现在拥有 25,324 股该生物制药公司的股票，价值为 279,000 美元，此前在上个季度又购买了 2,789 股。目前，99.10% 的股票由机构投资者和对冲基金持有。</p>
<h2>Theravance Biopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Theravance Biopharma 是一家生物制药公司，专注于创新药物的发现、开发和商业化，主要涉及呼吸疾病、炎症和免疫学以及罕见疾病领域。该公司开发的小分子疗法旨在通过靶向特定的分子通路来满足未满足的医疗需求。其主要市场产品 YUPELRI®（revefenacin）吸入溶液是美国批准的首个也是唯一一个每日一次的长效抗胆碱药（LAMA）。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Theravance Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Theravance Biopharma 吗？</h2>
<p>在你考虑 Theravance Biopharma 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Theravance Biopharma 并不在名单上。</p>
<p>虽然 Theravance Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Theravance生物制药

<p>Theravance Biopharma, Inc.（纳斯达克代码：TBPH）获得了八家研究公司的 “适度买入” 共识评级。分析师的评级包括四个持有、两个买入和两个强力买入，平均 12 个月目标价为 21.83 美元。最近的报告显示评级各异，Zacks 将评级上调至强力买入，B. Riley Financial 将目标价提高至 17.00 美元。该股票目前交易价格为 16.46 美元，市值为 8.4753 亿美元。机构投资者持有 99.10% 的股份，显示出对公司的强烈兴趣</p>

<p>Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the eight research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.8333.</p>
<div class="lb-trans"><p>Theravance Biopharma, Inc.（NASDAQ:TBPH - 获取免费报告）的股票在覆盖该股票的八家研究公司中获得了 “适度买入” 的平均评级，MarketBeat Ratings 报告称。四位分析师给予该股票持有评级，两位给予买入评级，两位给予强烈买入评级。在过去一年中，覆盖该股票的分析师的平均 12 个月目标价为 21.8333 美元。</p>
</div><p>Get <strong>Theravance Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Theravance Biopharma</strong> 的提醒：</p>
</div><p>TBPH has been the topic of several analyst reports. Zacks Research raised shares of Theravance Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, March 19th. B. Riley Financial upped their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, April 7th. TD Cowen upped their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a &#34;hold&#34; rating in a research report on Monday, March 23rd. Weiss Ratings lowered shares of Theravance Biopharma from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research report on Friday, April 10th. Finally, Oppenheimer downgraded shares of Theravance Biopharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, March 5th.</p>
<div class="lb-trans"><p>TBPH 已成为几份分析师报告的主题。Zacks Research 在 3 月 19 日的研究报告中将 Theravance Biopharma 的股票评级从 “持有” 上调至 “强烈买入”。B. Riley Financial 在 4 月 7 日的研究报告中将 Theravance Biopharma 的股票目标价从 14.00 美元上调至 17.00 美元，并给予该股票 “中性” 评级。TD Cowen 在 3 月 23 日的研究报告中将 Theravance Biopharma 的股票目标价从 13.00 美元上调至 15.00 美元，并给予该股票 “持有” 评级。Weiss Ratings 在 4 月 10 日的研究报告中将 Theravance Biopharma 的股票评级从 “买入（b-）” 下调至 “持有（c+）”。最后，Oppenheimer 在 3 月 5 日的报告中将 Theravance Biopharma 的股票评级从 “跑赢大盘” 下调至 “市场表现”。</p>
</div><p><strong>Check Out Our Latest Report on TBPH</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TBPH 的最新报告</strong></p>
</div><h2>Theravance Biopharma Trading Up 0.9%</h2>
<div class="lb-trans"><h2>Theravance Biopharma 股价上涨 0.9%</h2>
</div><p>NASDAQ TBPH opened at $16.46 on Friday. The firm's fifty day moving average price is $16.14 and its two-hundred day moving average price is $17.20. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The firm has a market capitalization of $847.53 million, a P/E ratio of 8.11 and a beta of 0.17.</p>
<div class="lb-trans"><p>NASDAQ TBPH 周五开盘价为 16.46 美元。该公司的 50 日移动平均价格为 16.14 美元，200 日移动平均价格为 17.20 美元。Theravance Biopharma 的一年低点为 8.33 美元，一年高点为 21.03 美元。该公司的市值为 8.4753 亿美元，市盈率为 8.11，贝塔值为 0.17。</p>
</div><h2>Insider Activity at Theravance Biopharma</h2>
<div class="lb-trans"><h2>Theravance Biopharma 的内部活动</h2>
</div><p>In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Theravance Biopharma 的新闻中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。这些股票以平均价格 13.96 美元出售，总价值为 433,695.32 美元。交易后，这位高级副总裁直接持有 232,699 股公司股票，价值为 3,248,478.04 美元。此次交易使其持股减少了 11.78%。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。目前，6.90% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Theravance Biopharma</h2>
<div class="lb-trans"><h2>对 Theravance Biopharma 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of TBPH. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma in the first quarter valued at about $101,000. Jane Street Group LLC grew its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Creative Planning acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock valued at $1,009,000 after buying an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after buying an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近修改了对 TBPH 的持股。AQR Capital Management LLC 在第一季度以约 101,000 美元的价格收购了 Theravance Biopharma 的新头寸。Jane Street Group LLC 在第一季度将其在 Theravance Biopharma 的股份增加了 169.2%。Jane Street Group LLC 现在拥有 140,884 股该生物制药公司的股票，价值为 1,258,000 美元，此前在上个季度又收购了 88,540 股。Creative Planning 在第二季度以约 139,000 美元的价格收购了 Theravance Biopharma 的新股份。American Century Companies Inc. 在第二季度将其在 Theravance Biopharma 的股份增加了 6.8%。American Century Companies Inc. 现在拥有 91,501 股该生物制药公司的股票，价值为 1,009,000 美元，此前在上个季度又购买了 5,794 股。最后，Invesco Ltd. 在第二季度将其在 Theravance Biopharma 的股份增加了 12.4%。Invesco Ltd. 现在拥有 25,324 股该生物制药公司的股票，价值为 279,000 美元，此前在上个季度又购买了 2,789 股。目前，99.10% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Theravance Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Theravance Biopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.</p>
<div class="lb-trans"><p>Theravance Biopharma 是一家生物制药公司，专注于创新药物的发现、开发和商业化，主要涉及呼吸疾病、炎症和免疫学以及罕见疾病领域。该公司开发的小分子疗法旨在通过靶向特定的分子通路来满足未满足的医疗需求。其主要市场产品 YUPELRI®（revefenacin）吸入溶液是美国批准的首个也是唯一一个每日一次的长效抗胆碱药（LAMA）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Theravance Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Theravance Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TBPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Theravance Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Theravance Biopharma 吗？</h2>
</div><p>Before you consider Theravance Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Theravance Biopharma 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Theravance Biopharma 并不在名单上。</p>
</div><p>While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Theravance Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Beat

奥本海默控股

景顺投资管理

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Theravance 生物制药公司（NASDAQ:TBPH）被券商一致评为 “适度买入”